Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-a65021751afedc04d4560394d8a23778"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-a65021751afedc04d4560394d8a23778"/>
<resource>
<Composition>
<id value="composition-en-a65021751afedc04d4560394d8a23778"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-a65021751afedc04d4560394d8a23778"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-a65021751afedc04d4560394d8a23778</b></p><a name="composition-en-a65021751afedc04d4560394d8a23778"> </a><a name="hccomposition-en-a65021751afedc04d4560394d8a23778"> </a><a name="composition-en-a65021751afedc04d4560394d8a23778-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/823/001 (5 single-dose inhalers)</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - adasuve</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/823/001 (5 single-dose inhalers)"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpa65021751afedc04d4560394d8a23778"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - adasuve"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What ADASUVE is and what it is used for</li><li>What you need to know before you use ADASUVE</li><li>How to use ADASUVE</li><li>Possible side effects</li><li>How to store ADASUVE</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What adasuve is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What adasuve is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>ADASUVE contains the active substance loxapine, which belongs to a group of medicines called antipsychotics. ADASUVE works by blocking certain chemicals in the brain (neurotransmitters) such as dopamine and serotonin thus causing calming effects and relieving aggressive behaviour.</p><p>ADASUVE is used to treat acute symptoms of mild-to-moderate agitation that may occur in adult patients who have schizophrenia or bipolar disorder. These are diseases characterised by symptoms such as:</p><ul><li>(Schizophrenia) Hearing, seeing, or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense.</li><li>(Bipolar disorder) Feeling high , having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas, and sometimes severe irritability.</li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take adasuve"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take adasuve"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use ADASUVE</p><ul><li>if you are allergic to loxapine or amoxapine;</li><li>if you have symptoms of wheezing or shortness of breath;</li><li>if you have lung problems like asthma or chronic obstructive pulmonary disease (which your doctor may have called COPD ).</li></ul><p>Warnings and precautions Your doctor or nurse will talk to you before you use ADASUVE and determine whether it is appropriate for you.</p><ul><li>ADASUVE may cause narrowing of the airways (bronchospasm) and may cause you to wheeze, cough, feel chest tightness or have shortness of breath. Typically, this may occur within minutes of use.</li><li>Neuroleptic Malignant Syndrome (NMS) is a set of symptoms that can occur if you are taking antipsychotic medicines, including ADASUVE. These symptoms can be high fever, rigid muscles,</li></ul><p>irregular or fast heart rate or pulse. NMS can cause death. Do not use ADASUVE again if NMS occurs.</p><ul><li>Antipsychotic medicines like ADASUVE can cause movements that you may not be able to control including making faces, sticking out your tongue, smacking or puckering your lips, blinking rapidly, or moving your legs, arms or fingers rapidly. Treatment with ADASUVE may have to be stopped if this occurs.</li><li>ADASUVE should be used with caution in patients who are intoxicated or delirious.</li></ul><p>Before treatment with ADASUVE, tell your doctor or nurse if you:</p><ul><li>have or had breathing problems like asthma or other chronic lung diseases such as bronchitis or emphysema</li><li>have or had heart problems or stroke</li><li>have or had low or high blood pressure</li><li>have or had seizures (convulsions)</li><li>have or had glaucoma (increased pressure in the eye)</li><li>have or had urinary retention (incomplete emptying of the bladder)</li><li>already used ADASUVE and you developed symptoms of wheezing or shortness of breath</li><li>ever had muscle or eye movements you can t control, lack of coordination, sustained muscle contraction, or feeling restless or unable to sit still</li><li>are an older person with dementia (loss of memory and other mental abilities).</li></ul><p>Children and adolescents ADASUVE is not for use in children and adolescents under 18 years.</p><p>Other medicines and ADASUVE Tell your doctor if you are using or have recently used or might use any other medicines, including:</p><ul><li>adrenaline</li><li>medicines to treat a breathing problem</li><li>medicines that may put you at a risk for seizures (for example, clozapine, tricyclics or SSRIs, tramadol, mefloquine)</li><li>medicines to treat Parkinson s disease</li><li>lorazepam or other centrally acting medicines (to treat anxiety, depression, pain, or to help you sleep) or any other medicines that cause sleepiness</li><li>recreational (illegal) drugs</li><li>medicines like fluvoxamine, propranolol, and enoxacin and other medicines that inhibit a certain liver enzyme called CYP450 1A2.</li><li>medicines to treat schizophrenia, depression, or pain since you may be more at risk for seizures Using ADASUVE and adrenaline together may cause your blood pressure to drop.</li></ul><p>ADASUVE with alcohol Because ADASUVE affects the nervous system, alcohol should be avoided when using ADASUVE.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. You should not breast-feed for a period of 48 hours after receiving ADASUVE and should discard the milk produced in the meantime.</p><p>The following symptoms may occur in newborn babies of mothers that have repeatedly used antipsychotic medicines in the last three months of their pregnancy: shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>Driving and using machines Do not drive or use any tools or machines after using ADASUVE until you know how ADASUVE affects you since dizziness, sedation, and sleepiness have been reported as a potential side effect of ADASUVE.</p></div>
</text>
</section>
<section>
<title value="3. How to take adasuve"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take adasuve"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor or nurse if you are not sure.</p><p>The recommended initial dose is 9.1 mg. After 2 hours, your doctor may prescribe a second dose after carefully considering your condition and your dose may be reduced to 4.5 mg if your doctor believes that this is a more appropriate dose to treat your condition.</p><p>You will use ADASUVE under the supervision of a doctor or nurse.</p><p>ADASUVE is for inhalation use. After the doctor or nurse has prepared ADASUVE for you to use, you will be asked to take the device in your hand, exhale and then put the mouthpiece in your mouth, inhale the medicine through the device and then hold your breath briefly.</p><p>If you use more ADASUVE than you should</p><p>If you are concerned that you are given more ADASUVE than you feel necessary, tell your doctor or nurse of your concern. Patients who have been given more ADASUVE than they should may experience any of the following symptoms: extreme tiredness or sleepiness, trouble breathing, low blood pressure, throat irritation or a bad taste in the mouth, muscle or eye movements you can t control.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you get any of the following side effects, talk to your doctor immediately and stop taking the medicine:</p><ul><li>any breathing symptoms such as wheezing, cough, shortness of breath, or chest tightness, as these could mean that the medicine is irritating your airways (uncommon occurrence unless you have asthma or COPD);</li><li>light-headedness or fainting, as these could mean that the medicine is lowering your blood pressure (uncommon occurrence);</li><li>worsening agitation or confusion, especially combined with fever or muscle stiffness (rare occurrence). These can be associated with a severe condition called neuroleptic malignant syndrome (NMS)</li></ul><p>Also talk to your doctor if you have any of the following side effects that could also happen with other forms of this medicine:</p><p>Very common (may affect more than 1 in 10 people): bad taste in the mouth or sleepiness.</p><p>Common (may affect up to 1 in 10 people): dizziness, throat irritation, dry mouth or tiredness.</p><p>Uncommon (may affect up to 1 in 100 people): muscle or eye movements you can t control, lack of coordination, sustained muscle contraction, or feeling restless or unable to sit still.</p><p>Additional side effects which have been related to long term use of loxapine by mouth and which may be relevant for ADASUVE include faintness upon standing, increased heart rate, increased blood pressure, blurred vision, dry eyes, and decreased urination.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store adasuve"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store adasuve"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use ADASUVE after the expiry date which is stated on the product label. The expiry date refers to the last day of that month.</p><p>Store in the original pouch until ready for use in order to protect from light and moisture.</p><p>Do not use ADASUVE if you notice an open or torn pouch or any signs of physical damage to the medicine.</p><p>Do not throw away any medicines via household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What ADASUVE contains<br/>The active substance is loxapine. Each single-dose inhaler contains 5 mg loxapine and delivers 4.5 mg of loxapine.</p><p>What ADASUVE looks like and contents of the pack ADASUVE 4.5 mg inhalation powder, pre-dispensed consists of a single-dose, disposable white plastic inhaler that contains loxapine. Each inhaler is packaged in a sealed foil pouch. ADASUVE 4.5 mg is supplied in a carton of 1 or 5 single dose inhalers.</p><p>Marketing Authorisation Holder Ferrer Internacional, S.A. Gran V a Carlos III, 08028- Barcelona Espa a</p><p>Manufacturer Ferrer Internacional, S.A. Joan Buscalla, 1-9, 08173 Sant Cugat del Vall s Barcelona, Spain</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien<br/>Ferrer Internacional, S.A. T l/Tel: +34 93 600 37 Lietuva<br/>AOP Orphan Pharmaceuticals GmbH Tel +370 672 12<br/>AOP Orphan Pharmaceuticals GmbH Te .: +35 988 6666Luxembourg/Luxemburg<br/>Ferrer Internacional, S.A. T l/Tel: +34 93 600 37 esk republika<br/>AOP Orphan Pharmaceuticals GmbH Tel: +420 251 512 Magyarorsz g<br/>AOP Orphan Pharmaceuticals GmbH Tel.: +36 1 3192Danmark<br/>Ferrer Internacional, S.A. Tlf: +34 93 600 37 Malta<br/>Ferrer Internacional, S.A. Tel.: +34 93 600 37 Deutschland<br/>Ferrer Deutschland GmbH Tel: +49 (0) 2407 502311 0</p><p>Nederland<br/>Ferrer Internacional, S.A. Tel.: +34 93 600 37 Eesti<br/>AOP Orphan Pharmaceuticals GmbH Tel: +370 672 12Norge<br/>Ferrer Internacional, S.A. Tlf: +34 93 600 37<br/>Ferrer Galenica S.A. : +30 210 52 81 sterreich<br/>AOP Orphan Pharmaceuticals GmbH Tel: +43 1 5037244-0</p><p>Espa a<br/>Ferrer Farma, S.A. Tel.: +34 93 600 37 Polska<br/>AOP Orphan Poland Sp. z o. o. Tel: +48 22 5428France<br/>Ferrer Internacional, S.A. T l: +34 93 600 37 Portugal<br/>Ferrer Portugal, S.A. Tel: +351 214449Hrvatska<br/>AOP Orphan Pharmaceuticals GmbH Tel: +43 1 5037244-0</p><p>Rom nia<br/>Galenica S.A. Tel: +30 210 52 81 Ireland<br/>Ferrer Internacional, S.A. Tel.: +34 93 600 37 Slovenija<br/>AOP Orphan Pharmaceuticals GmbH Tel: +43 1 5037244-0</p><p>sland<br/>Ferrer Internacional, S.A. S mi: +34 93 600 37 Slovensk republika<br/>AOP Orphan Pharmaceuticals GmbH Tel: +421 902 566Italia<br/>Angelini S.p.A. Tel: +39 06 780Suomi/Finland<br/>Ferrer Internacional, S.A. Puh/Tel: +34 93 600 37<br/>hespis Pharmaceutical Ltd T : ++357 22 67 77 Sverige<br/>Ferrer Internacional, S.A. Tel: +34 93 600 37 Latvija<br/>AOP Orphan Pharmaceuticals GmbH Tel +370 672 12This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpa65021751afedc04d4560394d8a23778"/>
<resource>
<MedicinalProductDefinition>
<id value="mpa65021751afedc04d4560394d8a23778"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpa65021751afedc04d4560394d8a23778"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpa65021751afedc04d4560394d8a23778</b></p><a name="mpa65021751afedc04d4560394d8a23778"> </a><a name="hcmpa65021751afedc04d4560394d8a23778"> </a><a name="mpa65021751afedc04d4560394d8a23778-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/823/001 (5 single-dose inhalers)</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: ADASUVE 4.5 mg inhalation powder, pre-dispensed</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/823/001 (5 single-dose inhalers)"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="ADASUVE 4.5 mg inhalation powder, pre-dispensed"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
